Endovascular Therapy for Renal Artery Stenosis in China
Endovascular Therapy for Renal Artery Stenosis in China
A multicenter prospective registry planned to recruit more than 5 000 patients with renal
 artery stenosis was carried out in China. This primary purpose of this study was to evaluate
 the safety and efficacy of renal artery revascularization in the real world. The secondary
 purpose was to investigate the etiologic distribution of renal artery stenosis and optimize
 the indications for renal artery revascularization.
Currently,the endovascular therapy of renal artery stenosis (especially atherosclerotic)
 remains in dispute. Some randomized control trials published in recent years (including
 ASTRAL and CORAL trials) showed the lack of additional benefit for renal artery
 revascularization compared with sole medical therapy. However,these randomized control trials
 presented a number of limitations including low numbers of patients and non-stringent
 inclusion criteria. Given clinical medical practice entering the era of big data, the
 large-sample real-word studies would be more objective to answer some pending issues of
 randomized controlled trial.Therefore,a multicenter prospective registry planned to recruit
 more than 5 000 patients with renal artery stenosis was carried out. This primary purpose of
 this study was to evaluate the safety and efficacy of renal artery revascularization in the
 real world. The secondary purpose was to investigate the etiologic distribution of renal
 artery stenosis and optimize the indications for renal artery revascularization.
Inclusion Criteria:

 1. Age ≥ 14 at the time of informed consent

 2. Diameter reduction of renal artery or main branch of renal artery≥ 60%,and ≥2 of four
 following conditions met:1)systolic hyperemic pressure gradient >20 mm Hg,2)captopril
 renoscitigraphy positive in the lesion side

 ,3)renin-angiotensin-aldosterone system significantly activated and 4)severe reduction
 (>25%) of glomendar filtration rate in the lesion side

 3. office systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg
 while receiving 3 antihypertensive drugs,or office systolic blood pressure ≥160 mmHg
 and/or diastolic blood pressure ≥100 mmHg without antihypertensive drugs

 4. Serum creatinine level<264umol/L

 5. Length of ipsilateral kidney ≥7.0 cm and glomendar filtration rate ≥10 ml／min

 6. Urine protein <2+

 Exclusion Criteria:

 1. Unable to provide informed consent

 2. Unstable condition and unable to tolerate interventional therapy

 3. intolerance to antiplatelet drugs or contrast medium

 4. vascular anatomy not suitable for endovascular therapy

 5. Pregnant, nursing, or planning to be pregnant